<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265511</url>
  </required_header>
  <id_info>
    <org_study_id>SCY-635-201</org_study_id>
    <nct_id>NCT01265511</nct_id>
  </id_info>
  <brief_title>Study of SCY-635, Pegasys and Copegus in Hepatitis C</brief_title>
  <official_title>A Phase 2a Study of SCY-635 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scynexis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scynexis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effectiveness of 28 days of triple combination therapy including&#xD;
      SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An&#xD;
      additional 20 weeks of treatment with the currently approved standard of care will be offered&#xD;
      to all participants. The Week 24 visit will be the last on-study visit. After the Week 24&#xD;
      visit, all subjects with undetectable HCV RNA will be given the option to continue treatment&#xD;
      with standard of care for an additional 24 weeks (out to Week 48) under the care of their&#xD;
      Principal Investigator.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      The primary objective of this Phase 2a study was to assess the effect of treatment with&#xD;
      SCY-635, used in combination with peginterferon alfa-2a (PegIFN α-2a) and ribavirin (RBV), on&#xD;
      hepatitis C viral replication (as measured by quantitative serum HCV RNA) in treatment-naive&#xD;
      subjects with chronic genotype 1 infection who have an IL28B genotype of C/T or T/T.&#xD;
&#xD;
      The secondary objective of the study was to evaluate the safety and pharmacokinetics (PK) of&#xD;
      SCY-635 when given in combination with PegIFN α-2a and RBV.&#xD;
&#xD;
      Primary Endpoints:&#xD;
&#xD;
      Proportion of subjects in each cohort with an undetectable serum HCV RNA level at Week 4 of&#xD;
      treatment&#xD;
&#xD;
      Secondary Endpoints:&#xD;
&#xD;
      Adverse events and clinical laboratory assessments, including tests of liver function&#xD;
      Proportion of subjects achieving complete early virologic response (cEVR, defined as an&#xD;
      undetectable serum HCV RNA level at Week 12) Proportion of subjects achieving partial early&#xD;
      virologic response (pEVR, defined as a detectable serum HCV RNA level with ≥ 2 log10&#xD;
      reduction in serum HCV RNA from Baseline to Week 12) Proportion of subjects achieving an&#xD;
      undetectable serum HCV RNA level at Week 24 Pharmacokinetic assessments of SCY-635 when given&#xD;
      in combination with PegIFN α-2a and RBV; trough concentrations of PegIFN α-2a and RB&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable HCV RNA</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Undetectable HCV RNA</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Early Virologic Response</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of subjects with detectable HCV RNA that achieve a &gt; or = 2 log reduction in HCV RNA from baseline to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Undetectable HCV RNA</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCY-635 600 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets given bid for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Batch # BMR/10/731</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCY-635</intervention_name>
    <description>SCY-635 tablets, 300 mg bid for 28 days</description>
    <arm_group_label>SCY-635 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegasys</intervention_name>
    <description>180 ug prefilled syringe given once per week for up to 48 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>SCY-635 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copegus</intervention_name>
    <description>tablets given bid for up to 48 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>SCY-635 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Quantifiable serum levels of HCV-specific RNA in excess of 100,000 IU/mL&#xD;
&#xD;
          -  Chronic HCV status&#xD;
&#xD;
          -  HCV genotype 1 infection and IL28B genotype of C/T or T/T&#xD;
&#xD;
          -  Liver biopsy results within 3 years prior to screening indicating the absence of&#xD;
             cirrhosis&#xD;
&#xD;
             *If no previous biopsy is available, a biopsy must be performed during the screening&#xD;
             period to qualify for randomization&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 38 kg/m2&#xD;
&#xD;
          -  Laboratory variables within acceptable ranges:&#xD;
&#xD;
               -  ALT/AST &lt; 3 × ULN;&#xD;
&#xD;
               -  HgB &gt; 12g/dL for females, &gt; 13 g/dL for males;&#xD;
&#xD;
               -  total WBC count &gt; 3000/mm3 and ANC &gt; 1500/mm3;&#xD;
&#xD;
               -  platelets &gt; 100,000/mm3;&#xD;
&#xD;
               -  prothrombin time (or INR) ≤ 1.2 × ULN;&#xD;
&#xD;
               -  serum albumin ≥ 3.4 g/dL;&#xD;
&#xD;
               -  total bilirubin WNL;&#xD;
&#xD;
               -  serum creatinine WNL; if serum creatinine is &gt; ULN, then calculated creatinine&#xD;
                  clearance must be &gt; 100 mL/min (by Cockcroft-Gault formula) for subject to be&#xD;
                  eligible&#xD;
&#xD;
          -  Subjects of childbearing potential (i.e., not surgically sterile or postmenopausal)&#xD;
             must agree to use 2 forms of contraception from Screening until 24 weeks after&#xD;
             completion of treatment with RBV&#xD;
&#xD;
          -  Negative urine testing for amphetamines and cocaine at Screening.&#xD;
&#xD;
          -  If female, the subject has a negative pregnancy test at Screening and on study Day 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant gastrointestinal, renal, hepatic, neurologic,&#xD;
             hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or&#xD;
             cardiovascular disease&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
&#xD;
          -  Males with partners who are pregnant or are planning to become pregnant&#xD;
&#xD;
          -  HCV genotype other than genotype 1 and an IL28B genotype of C/C&#xD;
&#xD;
          -  Seropositive for HIV-1 or HIV-2 or hepatitis B virus (HBV) surface antigen (HBsAg)&#xD;
&#xD;
          -  Use of any investigational agent within 3 months prior to dosing&#xD;
&#xD;
          -  Received any prior FDA-approved or investigational drug or drug regimen for the&#xD;
             treatment of hepatitis C&#xD;
&#xD;
          -  Evidence of cirrhosis on a previous liver biopsy&#xD;
&#xD;
          -  Evidence of decompensated liver disease&#xD;
&#xD;
          -  Recipient of an organ transplant&#xD;
&#xD;
          -  Evidence of hepatocellular carcinoma&#xD;
&#xD;
          -  Evidence of ongoing alcohol or substance abuse&#xD;
&#xD;
          -  Poorly-controlled diabetes mellitus&#xD;
&#xD;
          -  Congestive heart failure or unstable cardiopulmonary condition, renal disease, or&#xD;
             hemoglobinopathy (sickle cell anemia or thalassemia&#xD;
&#xD;
          -  History of seizure disorder&#xD;
&#xD;
          -  History of severe psychiatric illness, including severe depression, history of&#xD;
             suicidal ideation, suicidal attempts, related hospitalizations, bipolar disorder, or&#xD;
             psychosis requiring medication&#xD;
&#xD;
          -  Concurrent medical condition or laboratory abnormality that would constitute a&#xD;
             contra-indication for interferon use&#xD;
&#xD;
          -  History of unstable thyroid disease that would preclude administration of&#xD;
             interferon-based therapy&#xD;
&#xD;
          -  Medical condition that requires use of systemic corticosteroids&#xD;
&#xD;
          -  Received warfarin or other anticoagulants during the 21 days immediately prior to&#xD;
             Screening, or is expected to require warfarin or other anticoagulants during the&#xD;
             study.&#xD;
&#xD;
          -  One or more additional known primary or secondary causes of liver disease, other than&#xD;
             hepatitis C&#xD;
&#xD;
          -  Any other concurrent medical condition likely to preclude compliance with the schedule&#xD;
             of evaluations, or likely to confound the efficacy or safety observations&#xD;
&#xD;
          -  12-lead ECG showing the following:&#xD;
&#xD;
               -  Corrected QTc interval ≥ 450 msec (Bazett's correction);&#xD;
&#xD;
               -  QRS &gt; 120 msec;&#xD;
&#xD;
               -  Clinically significant abnormalities;&#xD;
&#xD;
          -  Severe retinopathy or other significant ophthalmological disorder&#xD;
&#xD;
          -  Use of any herbal supplements within 28 days prior to dosing.&#xD;
&#xD;
          -  The use of CYP3A inducers or inhibitors for at least 2 weeks prior to initiation of&#xD;
             treatment through Week 6&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Muir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keyur Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Ressearch Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigation de Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2010</study_first_posted>
  <results_first_submitted>October 22, 2014</results_first_submitted>
  <results_first_submitted_qc>July 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2017</results_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>SCY-635</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
Placebo: Oral tablets given bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>SCY-635 600 mg</title>
          <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
SCY-635: SCY-635 tablets, 300 mg bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met stopping rules</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
Placebo: Oral tablets given bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>SCY-635 600 mg</title>
          <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
SCY-635: SCY-635 tablets, 300 mg bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.0" spread="15.56"/>
                    <measurement group_id="B2" value="44.6" spread="8.67"/>
                    <measurement group_id="B3" value="45.1" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL28B genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IL28B_CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL28B_TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>HCV_1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV_1b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA</title>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.21" spread="0.05"/>
                    <measurement group_id="B2" value="6.3" spread="0.49"/>
                    <measurement group_id="B3" value="6.48" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Undetectable HCV RNA</title>
        <time_frame>Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
Placebo: Oral tablets given bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCY-635 600 mg</title>
            <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
SCY-635: SCY-635 tablets, 300 mg bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Undetectable HCV RNA</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Undetectable HCV RNA</title>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
Placebo: Oral tablets given bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCY-635 600 mg</title>
            <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
SCY-635: SCY-635 tablets, 300 mg bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Undetectable HCV RNA</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partial Early Virologic Response</title>
        <description>Proportion of subjects with detectable HCV RNA that achieve a &gt; or = 2 log reduction in HCV RNA from baseline to Week 12</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
Placebo: Oral tablets given bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCY-635 600 mg</title>
            <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
SCY-635: SCY-635 tablets, 300 mg bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Early Virologic Response</title>
          <description>Proportion of subjects with detectable HCV RNA that achieve a &gt; or = 2 log reduction in HCV RNA from baseline to Week 12</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Undetectable HCV RNA</title>
        <time_frame>Week 24</time_frame>
        <population>Week 24 analysis does not include the 2 placebo subjects because they were discontinued for lack of efficacy before week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
Placebo: Oral tablets given bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCY-635 600 mg</title>
            <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
SCY-635: SCY-635 tablets, 300 mg bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Undetectable HCV RNA</title>
          <population>Week 24 analysis does not include the 2 placebo subjects because they were discontinued for lack of efficacy before week 24.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
Placebo: Oral tablets given bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>SCY-635 600 mg</title>
          <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks&#xD;
SCY-635: SCY-635 tablets, 300 mg bid for 28 days&#xD;
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks&#xD;
Ribavirin: tablets given bid for up to 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Katyna Borroto-Esoda</name_or_title>
      <organization>Scynexis</organization>
      <phone>9192374431</phone>
      <email>katyna.borroto-esoda@scynexis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

